SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech fireworks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tuck2/12/2018 8:41:32 PM
   of 7424
 
Kadmon (KDMN) up ~20% after hours after reporting positive results in a proof of concept P2 study in IPF. However, questions arise, including a) why no p values; b) why did it take so long to enroll and read out for an one label study with a 24 week treatment period in 29 patients, which isn't even the targeted enrollment: and c) where are the baseline endpoint #s? They financed a few months ago, and we shouldn't necessarily figure on an opportunistic secondary here. CC tomorrow.

KD025 IPF P2 results

I don't really follow the company (but as an FGEN holder, paying some attention to the IPF space). So no opinion re long or short the news.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News